UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Time to initial cancer treatment in the United States and association with survival over time: An observational study

PloS one, 2019-03, Vol.14 (3), p.e0213209

2019

Volltextzugriff (PDF)

Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model

JCO precision oncology, 2019-12 (3), p.1-9

2019

Volltextzugriff (PDF)

A genetic basis for the variation in the vulnerability of cancer to DNA damage

Nature communications, 2016-04, Vol.7 (1), p.11428-11428, Article 11428

2016

Volltextzugriff (PDF)

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer

Proceedings of the National Academy of Sciences - PNAS, 2015-02, Vol.112 (5), p.1547-1552

2015

Volltextzugriff (PDF)

Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases

Scientific reports, 2021-09, Vol.11 (1), p.18174-18174, Article 18174

2021

Volltextzugriff (PDF)

Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab

Journal for immunotherapy of cancer, 2022-03, Vol.10 (3), p.e003778

2022

Volltextzugriff (PDF)

Prospective Clinical Study of Precision Oncology in Solid Tumors

JNCI : Journal of the National Cancer Institute, 2016-03, Vol.108 (3), p.1

2016

Volltextzugriff (PDF)

Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2022-10, Vol.40 (29), p.3353-3356

Pennell, Nathan A.

2022

Volltextzugriff (PDF)

Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab

Journal of thoracic oncology, 2018-11, Vol.13 (11), p.1771-1775

2018

Volltextzugriff (PDF)

Optimal predictive probability designs for randomized biomarker-guided oncology trials

Frontiers in oncology, 2022-12, Vol.12, p.955056-955056

2022

Volltextzugriff (PDF)

Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC

The oncologist (Dayton, Ohio), 2009-04, Vol.14 (4), p.399-411

2009

Volltextzugriff (PDF)

EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2014-11, Vol.86 (2), p.158-163

2014

Volltextzugriff (PDF)

Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers

Nature communications, 2019-11, Vol.10 (1), p.5143-14, Article 5143

2019

Volltextzugriff (PDF)

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials

Chest, 2017-08, Vol.152 (2), p.271-281

2017

Volltextzugriff (PDF)

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group

Journal of thoracic disease, 2018-07, Vol.10 (7), p.3909-3921

2018

Volltextzugriff (PDF)

Author Correction: Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases

Scientific reports, 2022-01, Vol.12 (1), p.1147-1147, Article 1147

2022

Volltextzugriff (PDF)

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib‐Responsive Non‐Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2015-11, Vol.20 (11), p.1298-1303

2015

Volltextzugriff (PDF)

Correction: Time to initial cancer treatment in the United States and association with survival over time: An observational study

PloS one, 2019-04, Vol.14 (4), p.e0215108-e0215108

2019

Volltextzugriff (PDF)

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation

The New England journal of medicine, 2022-07, Vol.387 (2), p.120-131

2022

Volltextzugriff (PDF)

Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer

Journal of the National Comprehensive Cancer Network, 2022-08, Vol.20 (8), p.953-961

2022

Volltextzugriff (PDF)

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)

Journal of thoracic oncology, 2018-09, Vol.13 (9), p.1393-1399

2018

Volltextzugriff (PDF)

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2020-08, Vol.383 (9), p.813-824

2020

Volltextzugriff (PDF)

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC

JTO clinical and research reports, 2022-07, Vol.3 (7), p.100359-100359, Article 100359

2022

Volltextzugriff (PDF)

Impact of Socioeconomic Factors on Overall Survival in SCLC

JTO clinical and research reports, 2022-07, Vol.3 (7), p.100360-100360, Article 100360

2022

Volltextzugriff (PDF)

Fast-Growing Plasmacytoma

The American journal of the medical sciences, 2016-03, Vol.351 (3), p.308-308

2016

Volltextzugriff (PDF)

1 – 25 von 247

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(229)
Mit Volltextzugriff
(213)

Publikationsform

Sprache

Englisch
(247)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

Science & Technology
(114)
Life Sciences & Biomedicine
(107)
Humans
(83)
Oncology
(78)
Lung Neoplasms - Drug Therapy
(36)
Male
(34)
Female
(32)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(30)
Aged
(29)
Respiratory System
(29)
Lung Cancer
(28)
Middle Aged
(28)
Lung Neoplasms - Genetics
(21)
Carcinoma, Non-Small-Cell Lung - Genetics
(19)
Immunotherapy
(17)
Lung Neoplasms - Pathology
(17)
Mutation
(17)
Adult
(16)
Chemotherapy
(16)
Carcinoma, Non-Small-Cell Lung - Pathology
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Time to initial cancer treatment in the United States and association with survival over time: An observational study

Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model

A genetic basis for the variation in the vulnerability of cancer to DNA damage

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer

Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases

Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab

Prospective Clinical Study of Precision Oncology in Solid Tumors

Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Non–Small-Cell Lung Cancer

Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab

Optimal predictive probability designs for randomized biomarker-guided oncology trials

Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC

EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC)

Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group

Author Correction: Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib‐Responsive Non‐Small Cell Lung Cancer

Correction: Time to initial cancer treatment in the United States and association with survival over time: An observational study

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation

Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC

Impact of Socioeconomic Factors on Overall Survival in SCLC

Fast-Growing Plasmacytoma

Suchergebnisse filtern